Clovis Oncology Inc. [NASDAQ: CLVS] traded at a low on 08/19/20, posting a -7.22 loss after which it closed the day’ session at $5.47. The company report on August 17, 2020 that Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations.
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations were published online in the Journal of Clinical Oncology. These results supported the May 2020 U.S. Food and Drug Administration (FDA) accelerated approval of Rubraca for the treatment of mCRPC patients who have a deleterious BRCA mutation (germline and/or somatic) and who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.
“Through publication in this prestigious journal, we are pleased to be able to share more detail about this important study, which we believe will be helpful for physicians as they consider treatment options for their mCRPC patients,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “The TRITON2 data underscore Rubraca’s role as a meaningful new treatment option for men with mCRPC and a deleterious germline or somatic BRCA mutation who have progressed on androgen receptor-directed therapy and taxane-based chemotherapy.”.
The results of the trading session contributed to over 4150373 shares changing hands. Over the past one week, the price volatility of Clovis Oncology Inc. stands at 10.70% while the volatility over the past one month is 7.30%.
The market cap for CLVS stock reached $489.01 million, with 80.45 million shares outstanding and 79.98 million shares in the current float. Compared to the average trading volume of 5.37M shares, CLVS reached a trading volume of 4150373 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Clovis Oncology Inc. [CLVS]?
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.43, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 3.07.
How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.76. With this latest performance, CLVS shares dropped by -12.70% in over the last four-week period, additionally sinking by -49.28% over the last 6 months – not to mention a drop of -9.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 42.95, with the RSI for the last a single of trading hit 45.79, and the three-weeks RSI is set at 43.30 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 6.38, while it was recorded at 5.37 for the last single week of trading, and 7.85 for the last 200 days.
Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Clovis Oncology Inc. [CLVS] shares currently have an operating margin of -256.85 and a Gross Margin at +75.75. Clovis Oncology Inc.’s Net Margin is presently recorded at -280.01.
Return on Total Capital for CLVS is now -58.15, given the latest momentum, and Return on Invested Capital for the company is -63.72. Additionally, CLVS Total Debt to Total Capital is recorded at 132.25, with Total Debt to Total Assets ending up at 106.72.
Reflecting on the efficiency of the workforce at the company, Clovis Oncology Inc. [CLVS] managed to generate an average of -$827,322 per employee. Receivables Turnover for the company is 5.74 with a Total Asset Turnover recorded at a value of 0.19.Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.90.
Earnings analysis for Clovis Oncology Inc. [CLVS]
With the latest financial reports released by the company, Clovis Oncology Inc. posted -1.72/share EPS, while the average EPS was predicted by analysts to be reported at -1.89/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clovis Oncology Inc. go to 71.60%.
Insider trade positions for Clovis Oncology Inc. [CLVS]
There are presently around $258 million, or 47.70% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: STATE STREET CORP with ownership of 9,238,731, which is approximately 151.719% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 6,244,924 shares of the stock with an approximate value of $34.13 million in CLVS stocks shares; and BLACKROCK INC., currently with $30.73 million in CLVS stock with ownership of nearly 48.319% of the company’s market capitalization.
98 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 18,660,799 shares. Additionally, 68 investors decreased positions by around 5,805,289 shares, while 26 investors held positions by with 22,763,643 shares. The mentioned changes placed institutional holdings at 47,229,731 shares, according to the latest SEC report filing. CLVS stock had 36 new institutional investments in for a total of 5,037,081 shares, while 31 institutional investors sold positions of 2,202,168 shares during the same period.